Journal Article

Ubiquinol Ameliorates Endothelial Dysfunction in Subjects with Mild-to-Moderate Dyslipidemia: A Randomized Clinical Trial

Tiano, Luca, Sabbatinelli, Jacopo, Olivieri, Fabiola, Mazzanti, Laura, Orlando, Patrick, Marcheggiani, Fabio, Giuliani, Angelica, Antonicelli, Roberto, Bonfigli, Anna Rita, Galeazzi, Roberta, Cirilli, Ilenia, Silvestri, Sonia, Dludla, Phiwayinkosi V.

2020

Overview

In this randomized, double-blind, single-center trial (ANZCTR number ACTRN12619000436178) we aimed to investigate changes in endothelium-dependent vasodilation induced by ubiquinol, the reduced form of coenzyme Q10 (CoQ10), in healthy subjects with moderate dyslipidemia. Fifty-one subjects with low-density lipoprotein (LDL) cholesterol levels of 130–200 mg/dL, not taking statins or other lipid lowering treatments, moderate (2.5%–6.0%) endothelial dysfunction as measured by flow-mediated dilation (FMD) of the brachial artery, and no clinical signs of cardiovascular disease were randomized to receive either ubiquinol (200 or 100 mg/day) or placebo for 8 weeks. The primary outcome measure was the effect of ubiquinol supplementation on FMD at the end of the study. Secondary outcomes included changes in FMD on week 4, changes in total and oxidized plasma CoQ10 on week 4 and week 8, and changes in serum nitrate and nitrite levels (NOx), and plasma LDL susceptibility to oxidation in vitro on week 8. Analysis of the data of the 48 participants who completed the study demonstrated a significantly increased FMD in both treated groups compared with the placebo group (200 mg/day, +1.28% ± 0.90%; 100 mg/day, +1.34% ± 1.44%; p < 0.001) and a marked increase in plasma CoQ10, either total (p < 0.001) and reduced (p < 0.001). Serum NOx increased significantly and dose-dependently in all treated subjects (p = 0.016), while LDL oxidation lag time improved significantly in those receiving 200 mg/day (p = 0.017). Ubiquinol significantly ameliorated dyslipidemia-related endothelial dysfunction. This effect was strongly related to increased nitric oxide bioavailability and was partly mediated by enhanced LDL antioxidant protection.

• Publisher: MDPI AG,MDPI
• Subject: Adult / Aged / Antioxidants / Atherosclerosis / bioavailability / Biological Availability / Blood pressure / blood serum / Brachial Artery - physiopathology / Cardiovascular disease / cardiovascular diseases / Cholesterol / Clinical trials / coenzyme Q10 / Diabetes / Double-Blind Method / Dyslipidemias - drug therapy / Dyslipidemias - physiopathology / Endothelium / Endothelium, Vascular - drug effects / Endothelium, Vascular - physiopathology / Female / Gene expression / High density lipoprotein / Homeostasis / Humans / hyperlipidemia / Laboratories / Lipids / Lipoproteins / low density lipoprotein / Male / Metabolic disorders / Middle Aged / nitrates / nitric oxide / Nitric Oxide - blood / Nitric Oxide - metabolism / nitrites / nutrients / oxidation / placebos / Plasma / Proteins / randomized clinical trials / Severity of Illness Index / signs and symptoms (animals and humans) / Triglycerides / Ubiquinone - administration & dosage / Ubiquinone - analogs & derivatives / Ubiquinone - pharmacology / vasodilation / Vasodilation - drug effects